Paper41576103
Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.
Rodrat M and 2 others. Proc Natl Acad Sci U S A, 2026. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant. Papers, record 41576103. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41576103
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant.
- PubMed
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cystic Fibrosis Transmembrane Conductance Regulator | Major topic |
| Cystic Fibrosis | Major topic |
| Quinolones | Major topic |
| Indoles | Major topic |
| Aminophenols | Major topic |
| Benzodioxoles | Major topic |
| Humans | |
| Pyridines | |
| Drug Combinations | |
| Mutation | |
| Pyrazoles | |
| Chloride Channel Agonists | |
| Patch-Clamp Techniques | |
| Pyrrolidines | |
| Quinolines |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| SRC 021 | Cystic Fibrosis Trust (CF) | PubMed |
Source PubMed
References62
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36499495 | Redefining Hypo- and Hyper-Responding Phenotypes of CFTR Mutants for Understanding and Therapy. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36499495 | PubMed |
| 2 | 2475911 | Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. | Science | 1989 | https://conductscience.org/library/papers/2475911 | PubMed |
| 3 | 29903467 | Combination potentiator ('co-potentiator') therapy for CF caused by CFTR mutants, including N1303K, that are poorly responsive to single potentiators. | J Cyst Fibros | 2018 | https://conductscience.org/library/papers/29903467 | PubMed |
| 4 | 1380673 | Processing of mutant cystic fibrosis transmembrane conductance regulator is temperature-sensitive. | Nature | 1992 | https://conductscience.org/library/papers/1380673 | PubMed |
| 5 | 21825083 | Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation. | Thorax | 2012 | https://conductscience.org/library/papers/21825083 | PubMed |
| 6 | 33775603 | Elexacaftor co-potentiates the activity of F508del and gating mutants of CFTR. | J Cyst Fibros | 2021 | https://conductscience.org/library/papers/33775603 | PubMed |
| 7 | 30334692 | VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. | N Engl J Med | 2018 | https://conductscience.org/library/papers/30334692 | PubMed |
| 8 | 12069690 | The human DnaJ homologue (Hdj)-1/heat-shock protein (Hsp) 40 co-chaperone is required for the in vivo stabilization of the cystic fibrosis transmembrane conductance regulator by Hsp70. | Biochem J | 2002 | https://conductscience.org/library/papers/12069690 | PubMed |
| 9 | 29581173 | Structural mechanisms of CFTR function and dysfunction. | J Gen Physiol | 2018 | https://conductscience.org/library/papers/29581173 | PubMed |
| 10 | 36543707 | Rescue by elexacaftor-tezacaftor-ivacaftor of the G1244E cystic fibrosis mutation's stability and gating defects are dependent on cell background. | J Cyst Fibros | 2023 | https://conductscience.org/library/papers/36543707 | PubMed |
| 11 | 31164398 | Identifying the molecular target sites for CFTR potentiators GLPG1837 and VX-770. | J Gen Physiol | 2019 | https://conductscience.org/library/papers/31164398 | PubMed |
| 12 | 33303536 | Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. | Eur Respir J | 2021 | https://conductscience.org/library/papers/33303536 | PubMed |
| 13 | 31205003 | Cystic fibrosis drug ivacaftor stimulates CFTR channels at picomolar concentrations. | Elife | 2019 | https://conductscience.org/library/papers/31205003 | PubMed |
| 14 | 22406676 | Allosteric modulation balances thermodynamic stability and restores function of ΔF508 CFTR. | J Mol Biol | 2012 | https://conductscience.org/library/papers/22406676 | PubMed |
| 15 | 15729345 | CFTR channel opening by ATP-driven tight dimerization of its nucleotide-binding domains. | Nature | 2005 | https://conductscience.org/library/papers/15729345 | PubMed |
| 16 | 36949202 | CFTR function, pathology and pharmacology at single-molecule resolution. | Nature | 2023 | https://conductscience.org/library/papers/36949202 | PubMed |
| 17 | 31776420 | Nanomolar-potency 'co-potentiator' therapy for cystic fibrosis caused by a defined subset of minimal function CFTR mutants. | Sci Rep | 2019 | https://conductscience.org/library/papers/31776420 | PubMed |
| 18 | 23891399 | Effect of ivacaftor on CFTR forms with missense mutations associated with defects in protein processing or function. | J Cyst Fibros | 2014 | https://conductscience.org/library/papers/23891399 | PubMed |
| 19 | 19846789 | Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. | Proc Natl Acad Sci U S A | 2009 | https://conductscience.org/library/papers/19846789 | PubMed |
| 20 | 21486785 | The most common cystic fibrosis-associated mutation destabilizes the dimeric state of the nucleotide-binding domains of CFTR. | J Physiol | 2011 | https://conductscience.org/library/papers/21486785 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42357359 | Interpreting the Black Box: Interpretable Machine Learning and Systems Pharmacology in Small-Molecule Therapeutics. | Pharmaceutics | 2026 | https://conductscience.org/library/papers/42357359 | PubMed |
| 41920076 | Altered functional interactions between CFTR disease mutants ΔF508 and G551D and the protein kinase A catalytic subunit. | J Physiol | 2026 | https://conductscience.org/library/papers/41920076 | PubMed |
| 41576103 | Chronic and acute modulator treatment restore wild-type-like activity and stability to the primary cystic fibrosis-causing CFTR variant. | Proc Natl Acad Sci U S A | 2026 | https://conductscience.org/library/papers/41576103 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CFTR | 1080 | PubTator's text mining | https://conductscience.org/library/genes/1080 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41576103
GET https://conductscience.org/api/papers/v1/41576103/references?page=2